Related Experiment Video
Updated: May 24, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Pharmacovigilance Assistant: An Agentic Workflow for Reproducible Drug Safety Summaries
Xabier Calle1,2, Naroa Mendez1, Alba Garin-Muga1,2
1Vicomtech Foundation, Basque Research and Technology Alliance, San Sebastian, Spain.
Abstract:
We present an agentic workflow that converts heterogeneous safety evidence into concise, reproducible drug summaries. While automated FAERS summarization, retrieval-augmented generation, and tool-driven agents exist in isolation, our contribution lies in their integration within a schema-aware, deterministic pipeline with explicit versioning and pharmacokinetic contextualization. The system queries FAERS via OpenFDA, integrates curated cytochrome P450 mappings, and can retrieve recent PubMed records. It normalizes fields, computes predefined aggregates, assesses enzyme overlap between index drugs and frequent co-medications, and generates constrained narratives and figures directly from computed tables. Applied to 110 drugs, the workflow recovered clear cross-drug patterns in severe outcomes and identified per-drug leaders for death and hospitalization. Case examples for clopidogrel and voriconazole illustrate how co-reporting patterns combined with CYP context provide mechanistic framing without implying causality. Deterministic execution, versioned queries, and cached responses enable exact reruns and audit. The workflow produces structured safety briefs that support safety committee review, early signal triage, and the selection of targets for confirmatory pharmacoepidemiologic studies.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Pharmaceutical Poisoning: Potential Scenarios
Bioequivalence studies: Biowaivers
Clinically Relevant Drug Product Specifications: Methods of Establishment
Dosage Regimens: Partial Pharmacokinetic Parameters
Bioavailability Study Design: Healthy Subjects Versus Patients
